Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Emerging Trends and their Impacts on Peptic Ulcer Diseases: Treatments and Techniques

Author(s): Pranjal Kumar Singh* and T.S. Easwari

Volume 17, Issue 1, 2022

Published on: 28 March, 2022

Page: [2 - 11] Pages: 10

DOI: 10.2174/1574885517666220307115813

Price: $65

Abstract

Background: Peptic ulcer disease (PUD) is prevalent in almost all parts of the world. PUD complications are a major source of health care expenses; however, they are preventable. The major factors responsible for the incidence of PUD and its complication have changed over the past few decades after the identification of non-steroidal inflammatory drugs (NSAIDs) and Helicobacter pylori bacterial infection along with a marked increase in the use of proton-pump inhibitors (PPIs) as drug therapy. The management of PUD has become more complex and challenging due to antimicrobial resistance.

Objectives: The objective of the study was to highlight current therapy and novel techniques used in the treatment of peptic ulcer diseases.

Methods: An exhaustive literature search has been conducted across PubMed, Google, Scopus and Web of Science electronic databases to extract the crucial information from the relevant literature.

Results: In the present review, we have discussed PUD and its pathophysiology. The recent trends in PUD and possible treatments with novel techniques have also been discussed. The type and presence of ulcers cannot be predicted accurately based on symptoms. The available treatment approaches for peptic ulcers based on their clinical presentation and etiology are anti-secretory therapy, endoscopy to reveal ulcers, followed by drug therapy, and triple therapy for H. pylori infection.

Conclusion: Thus, the popular and effective methods are very beneficial in controlling PUD. The treatment based on diagnosis is the foremost requirement for ameliorating any disorder. In this article, the emerging techniques and advancements in the treatment and diagnosis of PUD have been reviewed.

Keywords: Peptic ulcer, proton pump inhibitor, perforation, acidity, dyspepsia, NSAIDs, H. pylori.

« Previous Next »
Graphical Abstract

[1]
Xie J, Wang C, Wang N, et al. Graphdiyne nanoradioprotector with efficient free radical scavenging ability for mitigating radiation-induced gastrointestinal tract damage. Biomaterials 2020; 244 ,119940
[http://dx.doi.org/10.1016/j.biomaterials.2020.119940] [PMID: 32200103]
[2]
Wang H, Wei CX, Min L, Zhu LY. Good or bad: Gut bacteria in human health and diseases. Biotechnol Biotechnol Equip 2018; 32(5): 1075-80.
[http://dx.doi.org/10.1080/13102818.2018.1481350]
[3]
Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev 2017; 279(1): 70-89.
[http://dx.doi.org/10.1111/imr.12567] [PMID: 28856738]
[4]
Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V. Eosinophilic gastroenteritis: Diagnosis and clinical perspectives. Clin Exp Gastroenterol 2019; 12: 239-53.
[http://dx.doi.org/10.2147/CEG.S173130] [PMID: 31239747]
[5]
Aceves S, Collins MH, Rothenberg ME, et al. Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). J Allergy Clin Immunol 2020; 145(1): 28-37.
[http://dx.doi.org/10.1016/j.jaci.2019.11.012] [PMID: 31758958]
[6]
Dobos NM, Warrillow SJ. Gastrointestinal problems in intensive care. Anaesth Intensive Care Med 2021; 22(2): 95-100.
[http://dx.doi.org/10.1016/j.mpaic.2020.12.007]
[7]
Rai A, Gajula B, Kumar N, Malik A. Gastric perforation secondary to fungal gastritis in an immuno-competent adult. Cureus 2021; 13(2) ,e13156
[http://dx.doi.org/10.7759/cureus.13156] [PMID: 33692925]
[8]
Prabhu V, Shivani A. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. Ann Med Health Sci Res 2014; 4(1): 22-9.
[http://dx.doi.org/10.4103/2141-9248.126604] [PMID: 24669326]
[9]
Malik TF, Gnanapandithan K, Singh K. Peptic Ulcer DiseaseStatPearls. Treasure Island, FL: StatPearls Publishing 2021.
[10]
Malfertheiner P, Schulz C. Peptic ulcer: Chapter closed? Dig Dis 2020; 38(2): 1-5.
[PMID: 31905355]
[11]
Panigrahi MK, Singh A, Uthansingh K, et al. Clinical profile and risk factor of peptic ulcer disease in coastal eastern India. J Med Sci Clin Res 2018; 06(07): 615-20.
[12]
Gupta M, Kapoor B, Gupta R, Singh N. Plants and phytochemicals for treatment of peptic ulcer: An overview. S Afr J Bot 2021; 138: 105-14.
[http://dx.doi.org/10.1016/j.sajb.2020.11.030]
[13]
Serafim C, Araruna ME, Júnior EA, Diniz M, Hiruma-Lima C, Batista L. A review of the role of flavonoids in peptic ulcer (2010-2020). Molecules 2020; 25(22): 5431.
[http://dx.doi.org/10.3390/molecules25225431] [PMID: 33233494]
[14]
Ismail M, Khan F, Noor S, Shafi A. Management of gastrointestinal disorders and the pharmacist’s role: Peptic ulcer disease. Oxford: Elsevier 2019; pp. 389-407.
[15]
Ahmad AA, Kasim KF. Ma’Radzi AH, Gopinath SCB. Peptic ulcer: Current prospects of diagnostic and nanobiotechnological trends on pathogenicity. Process Biochem 2019; 85: 51-9.
[http://dx.doi.org/10.1016/j.procbio.2019.06.024]
[16]
Anwar I, Sadeeqa S. Peptic ulcer: Mini review with respect to case. Int J Vaccines Vaccin 2018; 5(2): 39-40.
[17]
Ban T, Khan PA, Fathima A. Effect of leaves and fruits of Moringa oleifera Lam on gastric and duodenal ulcers in rats. Br J Med Health Res 2016; 3(9): 137-48.
[18]
Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr 2017; 40(3): 91-3.
[http://dx.doi.org/10.18773/austprescr.2017.037] [PMID: 28798512]
[19]
Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: A case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7: 31-41.
[http://dx.doi.org/10.2147/DHPS.S71976] [PMID: 25653559]
[20]
Asali AM, Alghamdi MA, Fallatah SA, Alholaily WA, Aldandan RG, Alnosair AH, et al. Risk factors leading to peptic ulcer disease: Systematic review in literature. Int J Community Med Public Health 2018; 5(10): 4617-24.
[http://dx.doi.org/10.18203/2394-6040.ijcmph20183869]
[21]
Araújo MB, Borini P, Guimarães RC. Etiopathogenesis of peptic ulcer: Back to the past? Arq Gastroenterol 2014; 51(2): 155-61.
[http://dx.doi.org/10.1590/S0004-28032014000200016] [PMID: 25003270]
[22]
Desai JK, Goyal RK, Parmar NS. Pathogenesis of peptic ulcer disease and current trends in therapy. Indian J Physiol Pharmacol 1997; 41(1): 3-15.
[PMID: 10225026]
[23]
Graham DY, Khalaf N. Peptic ulcer disease.In: Pitchumoni C, Dharmarajan T, Eds Geriatric gastroenterology. Cham: Springer 2019.
[http://dx.doi.org/10.1007/978-3-319-90761-1_63-1]
[24]
Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives. Gut 2001; 49(3): 443-53.
[http://dx.doi.org/10.1136/gut.49.3.443] [PMID: 11511570]
[25]
Di Saverio S, Bassi M, Smerieri N, et al. Diagnosis and treatment of perforated or bleeding peptic ulcers: 2013 WSES position paper. World J Emerg Surg 2014; 9(1): 45.
[http://dx.doi.org/10.1186/1749-7922-9-45] [PMID: 25114715]
[26]
Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options. J Clin Med 2019; 8(2): 1-19.
[http://dx.doi.org/10.3390/jcm8020179] [PMID: 30717467]
[27]
Scarpignato C, Gatta L, Zullo A, et al. SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016; 14(1): 179.
[http://dx.doi.org/10.1186/s12916-016-0718-z] [PMID: 27825371]
[28]
Ahmed M, Mansoor T, Rab AZ, Rizvi SAA. Risk factors influencing postoperative outcome in patients with perforated peptic ulcer: A prospective cohort study. Eur J Trauma Emerg Surg 2022; 48(1): 81-6.
[http://dx.doi.org/10.1007/s00068-020-01597-6] [PMID: 33590271]
[29]
Ciftci F, Erözgen F. Patients with perforated peptic ulcers: Risk factors for morbidity and mortality. Int Surg 2018; 103(11-12): 578-84.
[http://dx.doi.org/10.9738/INTSURG-D-15-00180.1]
[30]
Søreide K, Thorsen K, Harrison EM, et al. Perforated peptic ulcer. Lancet 2015; 386(10000): 1288-98.
[http://dx.doi.org/10.1016/S0140-6736(15)00276-7] [PMID: 26460663]
[31]
Dadfar A, Edna TH. Epidemiology of perforating peptic ulcer: A population-based retrospective study over 40 years. World J Gastroenterol 2020; 26(35): 5302-13.
[http://dx.doi.org/10.3748/wjg.v26.i35.5302] [PMID: 32994689]
[32]
Gona SK, Alassan MK, Marcellin KG, et al. Postoperative morbidity and mortality of perforated peptic ulcer: Retrospective cohort study of risk factors among black Africans in Côte d’Ivoire. Gastroenterol Res Pract 2016; 2016 ,2640730
[33]
Bertleff MJ, Lange JF. Perforated peptic ulcer disease: A review of history and treatment. Dig Surg 2010; 27(3): 161-9.
[http://dx.doi.org/10.1159/000264653] [PMID: 20571260]
[34]
Chi TY, Zhu HM, Zhang M. Risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gastrointestinal bleeding resulting on people over 60 years old in Beijing. Medicine (Baltimore) 2018; 97(18) ,e0665
[http://dx.doi.org/10.1097/MD.0000000000010665] [PMID: 29718891]
[35]
Goh V. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res 2018; 11: 361-74.
[36]
Tarasconi A, Coccolini F, Biffl WL, et al. .Perforated and bleeding peptic ulcer : WSES guidelines. 2020; 9: 1-25.
[37]
Aitila P, Mutyaba M, Okeny S, et al. Prevalence and risk factors of helicobacter pylori infection among children aged 1 to 15 Years at holy innocents children’s hospital, mbarara, South Western Uganda. J Trop Med 2019; 2019 ,9303072
[38]
Lim SL, Canavarro C, Zaw MH, et al. Irregular meal timing is associated with helicobacter pylori infection and gastritis. Nutr 2013; 2013 ,714970
[http://dx.doi.org/10.5402/2013/714970]
[39]
Matsumoto H, Shiotani A, Graham DY. Current and future treatment of helicobacter pylori infections. Adv Exp Med Biol 2019; 1149: 211-25.
[http://dx.doi.org/10.1007/5584_2019_367] [PMID: 31016626]
[40]
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology 2018; 155(5): 1372-1382.e17.
[http://dx.doi.org/10.1053/j.gastro.2018.07.007] [PMID: 29990487]
[41]
Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: A prospective study. BMC Infect Dis 2019; 19(1): 447.
[http://dx.doi.org/10.1186/s12879-019-4085-1] [PMID: 31113384]
[42]
Qaria MA, Qumar S, Sepe LP, Ahmed N. Cholesterol glucosylation-based survival strategy in Helicobacter pylori. Helicobacter 2021; 26(2) ,e12777
[http://dx.doi.org/10.1111/hel.12777] [PMID: 33368895]
[43]
Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: The power of nanosized formulations. Nanomedicine (Lond) 2020; 15(5): 527-42.
[http://dx.doi.org/10.2217/nnm-2019-0329] [PMID: 32028847]
[44]
Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. Am J Med 2019; 132(4): 447-56.
[http://dx.doi.org/10.1016/j.amjmed.2018.12.009] [PMID: 30611829]
[45]
Yeğen BC. Lifestyle and peptic ulcer disease. Curr Pharm Des 2018; 24(18): 2034-40.
[http://dx.doi.org/10.2174/1381612824666180510092303] [PMID: 29745325]
[46]
Tulchinsky TH. In: Chapter 22 -Warren, Marshall, Helicobacter pylori, Peptic Ulcers and Gastric Cancer.In: Tulchinsky THBT-CS in PH. USA: Academic Press 2018; pp. 543-60.
[47]
Mahmood KT, Sara S, Shifa H. Eating habits a risk factor to peptic ulcer. J Pharm Sci Res 2011; 3(1): 903-10.
[48]
Hasneen DF, Zaki NL, Abbas MS, Soliman AS, Ashoush IS, Fayed AE. Comparative evaluation of some herbs and their suitability for skimmed milk yoghurt and cast Kariesh cheese fortification as functional foods. Ann Agric Sci 2020; 65(1): 6-12.
[http://dx.doi.org/10.1016/j.aoas.2020.05.001]
[49]
Chen S, Wang J, Li Y. Is alcohol consumption associated with gastroesophageal reflux disease? J Zhejiang Univ Sci B 2010; 11(6): 423-8.
[50]
Mandalari G, Bisignano C, Cirmi S, Navarra M. Effectiveness of citrus fruits on helicobacter pylori. Evid Based Complement Alternat Med 2017; 2017 ,8379262
[http://dx.doi.org/10.1155/2017/8379262] [PMID: 28408943]
[51]
Vomero ND, Colpo E. Nutritional care in peptic ulcer. Arq Bras Cir Dig 2014; 27(4): 298-302.
[http://dx.doi.org/10.1590/S0102-67202014000400017] [PMID: 25626944]
[52]
Fokunang CN, Tembe E, Frederick K, Ngadjui B. Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries. Toxicology 2018; 4(1): 5-13.
[53]
Kim TJ, Kim ER, Hong SN, et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep 2019; 9(1): 11696.
[http://dx.doi.org/10.1038/s41598-019-48173-6] [PMID: 31406189]
[54]
Li Z, Wang Z, Shen B, Chen C, Ding X, Song H. Effects of aspirin on the gastrointestinal tract: Pros vs. cons. Oncol Lett 2020; 20(3): 2567-78.
[http://dx.doi.org/10.3892/ol.2020.11817] [PMID: 32782574]
[55]
Vella V, Hons BP, Clin P, Aberdeen P. Drug-induced peptic ulcer disease. J Malta College Pharm Practice 2005; 10: 15-9.
[56]
Watanabe T, Fujiwara Y, Chan FKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: A comprehensive review. J Gastroenterol 2020; 55(5): 481-95.
[http://dx.doi.org/10.1007/s00535-019-01657-8] [PMID: 31865463]
[57]
Sánchez AB, Clares B, Rodríguez-Lagunas MJ, Fábrega MJ, Calpena AC. Study of melatonin as preventive agent of gastrointestinal damage induced by sodium diclofenac. Cells 2020; 9(1): 1-17.
[http://dx.doi.org/10.3390/cells9010180] [PMID: 31936877]
[58]
Vertzoni M, Augustijns P, Grimm M, et al. Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. Eur J Pharm Sci 2019; 134: 153-75.
[http://dx.doi.org/10.1016/j.ejps.2019.04.013] [PMID: 30991092]
[59]
Chatterjee A, Bandyopadhyay SK. Herbal remedy: An alternate therapy of nonsteroidal anti-inflammatory drug induced gastric ulcer healing. Ulcers 2014; 2014 ,361586
[60]
Takeuchi K, Amagase K. Roles of prostaglandin E and EP receptors in mucosal protection and ulcer healing in the gastrointestinal tract. Arch Dig Disord 2017; 1(2): 8-16.
[61]
Sumathy C, Vijayakumar N. Review on antiulcerogenic activity of musa sapientum on experimental peptic ulcers in rats. World J Pharm Res 2015; 4(5): 832-46.
[62]
Magierowski M, Magierowska K, Kwiecien S, Brzozowski T. Gaseous mediators nitric oxide and hydrogen sulfide in the mechanism of gastrointestinal integrity, protection and ulcer healing. Molecules 2015; 20(5): 9099-123.
[http://dx.doi.org/10.3390/molecules20059099] [PMID: 25996214]
[63]
Patil KR, Mahajan UB, Unger BS, et al. Animal models of inflammation for screening of anti-inflammatory drugs: Implications for the discovery and development of phytopharmaceuticals. Int J Mol Sci 2019; 20(18): 4367-71.
[http://dx.doi.org/10.3390/ijms20184367] [PMID: 31491986]
[64]
Yasuda H, Matsuo Y, Sato Y, et al. Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med 2015; 4(1): 40-6.
[http://dx.doi.org/10.5492/wjccm.v4.i1.40] [PMID: 25685721]
[65]
Knopp-Sihota JA, Cummings GG, Homik J, Voaklander D. The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: A population-based nested cohort study. BMC Geriatr 2013; 13(1): 36.
[http://dx.doi.org/10.1186/1471-2318-13-36] [PMID: 23602075]
[66]
Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: A nationwide population-based case-crossover study. Aliment Pharmacol Ther 2015; 42(5): 599-606.
[http://dx.doi.org/10.1111/apt.13298] [PMID: 26096497]
[67]
Gutermann IK, Niggemeier V, Zimmerli LU, Holzer BM, Battegay E, Scharl M. Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: Systematic search for clinical practice guidelines. Medicine (Baltimore) 2015; 94(1) ,e377
[http://dx.doi.org/10.1097/MD.0000000000000377] [PMID: 25569664]
[68]
Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11): 1954-63.
[http://dx.doi.org/10.3748/wjg.v23.i11.1954] [PMID: 28373761]
[69]
Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 2000; 18(3): 463-7.
[http://dx.doi.org/10.1200/JCO.2000.18.3.463] [PMID: 10653861]
[70]
Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: What radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258(1): 41-56.
[http://dx.doi.org/10.1148/radiol.10092129] [PMID: 21183492]
[71]
Nikshoar M, Rastegarpour A, Kolahi A. The characteristics of gastroduodenal perforations in crack-heroin users social determinants of health research centre. Aust J Basic Appl Sci 2013; 7(4): 703-7.
[72]
Ogasawara O, Kojima T, Miyazu M, Sobue K. Impact of the stress ulcer prophylactic protocol on reducing the unnecessary administration of stress ulcer medications and gastrointestinal bleeding: A single-center, retrospective pre-post study. J Intensive Care 2020; 8(1): 10.
[http://dx.doi.org/10.1186/s40560-020-0427-8] [PMID: 31988751]
[73]
Plummer MP, Blaser AR, Deane AM. Stress ulceration: Prevalence, pathology and association with adverse outcomes. Crit Care 2014; 18(2): 213.
[http://dx.doi.org/10.1186/cc13780] [PMID: 25029573]
[74]
Alshami A, Barona SV, Varon J, Surani S. Gastrointestinal stress ulcer prophylaxis in the intensive care unit, where is the data? World J Metaanal 2019; 7(3): 72-6.
[http://dx.doi.org/10.13105/wjma.v7.i3.72]
[75]
Zhang W, Lu H, Graham DY. An update on Helicobacter pylori as the cause of gastric cancer. Gastrointest Tumors 2014; 1(3): 155-65.
[http://dx.doi.org/10.1159/000365310] [PMID: 26672968]
[76]
Nishizawa T, Suzuki H. Gastric carcinogenesis and underlying molecular mechanisms: Helicobacter pylori and novel targeted therapy. Biomed Res Int 2015; 2015 ,794378
[77]
Bauer B, Meyer TF. The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease. Ulcers 2011. ,340157
[78]
Kaul V. Gastric cancer risk in helicobacter pylori infected patients. World J Gastrointest Oncol 2015; 4(1): 196-205.
[79]
Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. Helicobacter pylori-induced gastric pathology: Insights from in vivo and ex vivo models. Dis Model Mech 2017; 10(2): 89-104.
[http://dx.doi.org/10.1242/dmm.027649] [PMID: 28151409]
[80]
Muzaheed. Helicobacter pylori oncogenicity: Mechanism, prevention, and risk factors. lIn: Sci World J 2020; 2020 ,3018326
[81]
Chan KS, Wang YL, Chan XW, Shelat VG. Outcomes of omental patch repair in large or giant perforated peptic ulcer are comparable to gastrectomy. Eur J Trauma Emerg Surg 2021; 47(6): 1745-52.
[PMID: 31612272]
[82]
Ansari D, Torén W, Lindberg S, Pyrhönen H-S, Andersson R. Diagnosis and management of duodenal perforations: A narrative review. Scand J Gastroenterol 2019; 54(8): 939-44.
[http://dx.doi.org/10.1080/00365521.2019.1647456] [PMID: 31353983]
[83]
Kumar P, Khan HM, Hasanrabba S. Treatment of perforated giant gastric ulcer in an emergency setting. World J Gastrointest Surg 2014; 6(1): 5-8.
[http://dx.doi.org/10.4240/wjgs.v6.i1.5]
[84]
Chung KT, Shelat VG. Perforated peptic ulcer - an update. World J Gastrointest Surg 2017; 9(1): 1-12.
[http://dx.doi.org/10.4240/wjgs.v9.i1.1] [PMID: 28138363]
[85]
Scotti E, Boué S, Lo Sasso G, et al. Exploring the microbiome in health and disease: Implications for toxicology. Toxicol Res Appl 2017; 1 ,2397847317741884
[http://dx.doi.org/10.1177/2397847317741884]
[86]
Ierardi E, Losurdo G, Fortezza RF, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-104.
[http://dx.doi.org/10.3748/wjg.v25.i34.5097] [PMID: 31558859]
[87]
Hussein M, Alzoubaidi D, Lopez MF, et al. Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer-related bleeding: Multicenter international registry. Endoscopy 2021; 53(1): 36-43.
[http://dx.doi.org/10.1055/a-1186-5360] [PMID: 32459000]
[88]
Khoder G, Menhali AA, Yassir FAL, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med 2016; 12(1): 3-17.
[http://dx.doi.org/10.3892/etm.2016.3293]
[89]
Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: Antibiotics or probiotics. Appl Microbiol Biotechnol 2018; 102(1): 1-7.
[http://dx.doi.org/10.1007/s00253-017-8535-7] [PMID: 29075827]
[90]
Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: A placebo-controlled, single-blind study. BMC Nutr 2018; 4(1): 48.
[http://dx.doi.org/10.1186/s40795-018-0257-4] [PMID: 32153909]
[91]
Jain A, Jain P, Parihar DK. Comparative study of in-vitro antidiabetic and antibacterial activity of non-conventional curcuma species. J Biol Active Prod Nat 2019; 9(6): 457-64.
[http://dx.doi.org/10.1080/22311866.2019.1710253]
[92]
Jain A, Parihar DK. Antibacterial, biofilm dispersal and antibiofilm potential of alkaloids and flavonoids of Curcuma. Biocatal Agric Biotechnol 2018; 16: 677-82.
[http://dx.doi.org/10.1016/j.bcab.2018.09.023]
[93]
Jain A, Parihar DK. Molecular marker based genetic diversity study of wild, cultivated and endangered species of Curcuma from Chhattisgarh region for in situ conservation. Biocatal Agric Biotechnol 2019; 18 ,101033
[http://dx.doi.org/10.1016/j.bcab.2019.101033]
[94]
Kumar V, Rathore K, Jain P, Ahmed Z. Biological activity of Bauhinia racemose against diabetes and interlinked disorders like obesity and hyperlipidemia. Clin Phytosci 2017; 3(1): 7.
[http://dx.doi.org/10.1186/s40816-017-0044-9]
[95]
Kumar V, Jain P, Rathore K, Ahmed Z. Biological evaluation of Pupalia lappacea for antidiabetic, antiadipogenic, and hypolipidemic activity both in vitro and in vivo. Scientifica (Cairo) 2016; 2016 ,1062430
[http://dx.doi.org/10.1155/2016/1062430] [PMID: 26942038]
[96]
Rathore K, Singh V, Jain P, Rao SP, Ahmed Z, Thakur VS. In-vitro and in-vivo antiadipogenic, antidiabetic and hypolipidemic activity of Diospyros melanoxylon (Roxb.). J Ethnopharmacol 2014; 155: 1171-6.
[http://dx.doi.org/10.1016/j.jep.2014.06.050] [PMID: 25010927]
[97]
Jain P, Satapathy T, Pandey RK. Acaricidal activity and clinical safety of arecoline hydrobromide on calves infested with cattle tick Rhipicephalus microplus (Acari: Ixodidae). Vet Parasitol 2021; 298 ,109490
[http://dx.doi.org/10.1016/j.vetpar.2021.109490] [PMID: 34271319]
[98]
Jain P, Satapathy T, Pandey RK. First report on efficacy of Citrus limetta seed oil in controlling cattle tick Rhipicephalus microplus in red Sahiwal calves. Vet Parasitol 2021; 296 ,109508
[http://dx.doi.org/10.1016/j.vetpar.2021.109508] [PMID: 34218174]
[99]
Jain P, Satapathy T, Kumar R. Acaricidal activity and biochemical analysis of Citrus limetta seed oil for controlling ixodid tick rhipicephalus microplus infesting cattle. Syst Appl Acarol 2021; 2021: 26.
[http://dx.doi.org/10.11158/saa.26.7.13]
[100]
Jain P, Satapathy T, Pandey RK. Rhipicephalus microplus (acari: Ixodidae): Clinical safety and potential control by topical application of cottonseed oil (Gossypium sp.) on cattle. Exp Parasitol 2020; 219 ,108017
[http://dx.doi.org/10.1016/j.exppara.2020.108017] [PMID: 33039477]
[101]
Jain P, Satapathy T, Pandey RK. Rhipicephalus microplus: A parasite threatening cattle health and consequences of herbal acaricides for upliftment of livelihood of cattle rearing communities in Chhattisgarh. Biocatal Agric Biotechnol 2020; 26 ,101611
[http://dx.doi.org/10.1016/j.bcab.2020.101611]
[102]
Jain P, Satapathy T, Pandey RK. Efficacy of arecoline hydrobromide against cattle tick Rhipicephalus (Boophilus) microplus. Int J Acarol 2020; 46(4): 268-75.
[http://dx.doi.org/10.1080/01647954.2020.1765018]
[103]
Jain P, Satapathy T, Pandey RK. First report on ticks (Acari: Ixodidae) controlling activity of cottonseed oil (Gossypium Sp.). Int J Acarol 2020; 46(4): 263-7.
[http://dx.doi.org/10.1080/01647954.2020.1767203]
[104]
Jain P, Satapathy T, Pandey RK. A mini review of methods to control ticks population infesting cattle in Chhattisgarh with special emphasis on herbal acaricides. IJNPR 2020; 11(12): 217-23.
[105]
Sharwan G, Jain P, Pandey R, Shukla SS. Toxicity and safety profiles of methanolic extract of Pistacia integerrima J.L. stewart ex brandis (pi) for wistar rats. J Pharmacopuncture 2016; 19(3): 253-8.
[http://dx.doi.org/10.3831/KPI.2016.19.027] [PMID: 27695635]
[106]
Jain P, Pandey R, Shukla SS. Reproductive and developmental toxicity study of talisadya churna: An ancient polyherbal formulation. IAJPR 2016; 6(5): 5641-53.
[107]
Jain P, Pandey R, Shukla SS. Acute and subacute toxicity studies of polyherbal formulation talisadya churna in experimental animal model. MJPMS 2015; 1(1): 7-10.
[108]
Sharwan G, Jain P, Pandey R, Shukla SS. Toxicity profile of traditional herbal medicine. J Ayu Herb Med 2015; 1(3): 81-90.
[109]
Jain P, Rao SP, Singh V, Pandey R, Shukla SS. Acute and subacute toxicity studies of an ancient ayurvedic formulation: Agnimukha churna. CJPS 2014; (1): 18-22.
[110]
Rao SP, Amrit I, Jain P, Singh V. Antiulcer activity of Agnimukha churna. Int J Ayurveda Pharma Res 2014; 2(2): 40-6.
[111]
Jain P. Secondary metabolites for antiulcer activity. Nat Prod Res 2016; 30(6): 640-56.
[PMID: 25920371]
[112]
Gölder S, Neuhas L, Freuer D, et al. Over-the-scope clip in peptic ulcer bleeding: Clinical success in primary and secondary treatment and factors associated with treatment failure. Endosc Int Open 2019; 7(6): E846-54.
[http://dx.doi.org/10.1055/a-0898-3357]
[113]
Grupka MJ, Benson J. Endoscopic clipping. J Dig Dis 2008; 9(2): 72-8.
[http://dx.doi.org/10.1111/j.1751-2980.2008.00325.x] [PMID: 18419639]
[114]
Becq A, Rahmi G, Perrod G, Cellier C. Hemorrhagic angiodysplasia of the digestive tract: Pathogenesis, diagnosis, and management. Gastrointest Endosc 2017; 86(5): 792-806.
[http://dx.doi.org/10.1016/j.gie.2017.05.018]
[115]
Karaman A, Baskol M, Gursoy S, et al. Epinephrine plus argon plasma or heater probe coagulation in ulcer bleeding. World J Gastroenterol 2011; 17(36): 4109-12.
[http://dx.doi.org/10.3748/wjg.v17.i36.4109]
[116]
Cho YS. New endoscopic techniques in treating gastrointestinal bleeding. Gastrointest Interv 2018; 7(3): 131-5.
[http://dx.doi.org/10.18528/gii180025]
[117]
Jacques J, Legros R, Chaussade S, Sautereau D. Endoscopic haemostasis: An overview of procedures and clinical scenarios. Dig Liver Dis 2014; 46(9): 766-76.
[http://dx.doi.org/10.1016/j.dld.2014.05.008] [PMID: 25022337]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy